Georgia Tech startup LymphaTech

Early-stage startup has developed technology to detect early onset lymphedema

Contact
No contact information submitted.
Sidebar Content
No sidebar content submitted.
Summaries

Summary Sentence:

Early-stage startup has developed technology to detect early onset lymphedema

Full Summary:

Early-stage startup has developed technology to detect early onset lymphedema

LymphaTech is an early-stage startup that has developed an innovative optical diagnostic to detect lymphedema, a side effect of breast cancer surgery, which affects nearly 50% of all breast cancer survivors. Lymphedema causes dramatic and irreversible arm swelling, subsequently leading to pain, depression, and reduced quality of life. There is currently no technology on the market that can detect the onset of lymphedema before permanent tissue damage has already occurred. Lymphatech’s diagnostic can detect lymphedema before symptoms begin, which will allow doctors to begin therapy and prevent permanent tissue damage, thus dramatically improving the standard of care for breast cancer survivors.

The startup company is based on technology developed in the lab of Brandon Dixon, an assistant professor in the George W. Woodruff School of Mechanical Engineering. The founder of the company is fourth-year Georgia Tech bioengineering PhD candidate, Mike Weiler. The company formed through the joint Emory-Georgia Tech TI:GER program (Technological Innovation: Generating Economic Results) which is a program that joins PhDs, MBAs, and JDs to commercialize university research technologies.

Related Links

Additional Information

Groups

Parker H. Petit Institute for Bioengineering and Bioscience (IBB)

Categories
No categories were selected.
Related Core Research Areas
Bioengineering and Bioscience
Newsroom Topics
No newsroom topics were selected.
Keywords
No keywords were submitted.
Status
  • Created By: Colly Mitchell
  • Workflow Status: Draft
  • Created On: Feb 18, 2014 - 4:10am
  • Last Updated: Oct 7, 2016 - 11:15pm